Simvatstatin Used to Treat Pulmonary Hypertension

• Sponsor: Capital Medical University (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT00538044
• Collaborator: (none)
• Location: 1
• Arms: 2
• Duration (Months): 36

Study Details

Study Description

Brief Summary

we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Condition or Disease	Intervention/Treatment	Phase
Hypertension, Pulmonary	Drug: simvastatin	Phase 1

Detailed Description

advanced pulmonary hypertension is refractory to the medication in use nowaday, especially pulmonary hypertension secondary to congenital heart disease or chronic pulmonary embolism.It is revealed that statins may intefere the pathogenisis of the pulmonary hypertension in many key poing, such as improving apotosis or inhiting the proliferation of pulmonary vascular smooth muscle cell. so we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Study Design

• Study Type: Interventional
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Investigator)
• Primary Purpose: Treatment
• Official Title: the Clinical Research Using Simvastatin as a Medication to Treat Advanced Secondary Pulmonary Hypertension
• Study Start Date: Jan 1, 2009
• Anticipated Study Completion Date: Jan 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1simvastatin group before the operation, the patient start the simvastatin medication on the dosage of 40mg per day	Drug: simvastatin; medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
No Intervention: 2contral group just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group

Outcome Measures

Primary Outcome Measures

1. the simvastatin can alleviate pulmonary hypertension []

2. pulmonary pressure []

Secondary Outcome Measures

1. simvastatin can highten the perioperative and long term survaval rate and the living quality []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 12 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• pasp>50mmHg

Exclusion Criteria:

• pasp<50mmhg

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Beijing Anzhen Hospital	Beijing		China	100029

Sponsors and Collaborators

• Capital Medical University

Investigators

• Study Chair: Huili Gan, MD,Ph.D., Beijing Anzehn Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00538044
• Other Study ID Numbers: Gan1; Anzhen1
• First Posted: Oct 2, 2007
• Last Update Posted: Oct 2, 2007
• Last Verified: Sep 1, 2007

• Keywords provided by , ,: pulmonary hypertension; simvastatin; advanced pulmonary hypertension secondary to congenital heart disease; advanced pulmonary hypertension secondary to chronic pulmonary embolism
• Additional relevant MeSH terms: Hypertension, Pulmonary; Hypertension; Simvastatin

Study Results

No Results Posted as of Oct 2, 2007